Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
15 results
  • Lymphoma, Cellular Therapy

18-455          Phase III

A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (Transform) (View details on clinicaltrial.gov)

  • Cellular Therapy, Head and Neck Cancer

17-193          Phase III

A Multicentre, Randomized, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr Virusspecific Autologous Cytotoxic T Lymphocytes versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients (View details on clinicaltrial.gov)

  • Bladder Cancer, Cellular Therapy, Metastatic/Advanced Cancer, Lung Cancer

17-553          Phase I

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers (View details on clinicaltrial.gov)

  • Multiple Myeloma, Cellular Therapy

17-379          Phase I

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Cellular Therapy, Lymphoma

15-404          Phase I

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (View details on clinicaltrial.gov)

  • Cellular Therapy, Multiple Myeloma

19-156          Phase II

A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma, Cellular Therapy

18-604          Phase II

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2). (View details on clinicaltrial.gov)

  • Cellular Therapy, Liver Cancer

17-033          Phase I

A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) (View details on clinicaltrial.gov)

  • Cellular Therapy, Lung Cancer

15-502          Phase II

A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) (View details on clinicaltrial.gov)

  • Head and Neck Cancer, Cellular Therapy

19-027          Phase II

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma (View details on clinicaltrial.gov)

Showing 1 - 10 of 15 results